Experienced in Leukemia

Dr. Josephine H. Haduong

Pediatric Hematology Oncology
1201 West La Veta Avenue, 
Orange, CA 
Accepting New Patients
Experienced in Leukemia
1201 West La Veta Avenue, 
Orange, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Josephine Haduong is a Pediatric Hematologist Oncology provider in Orange, California. Dr. Haduong is rated as an Experienced provider by MediFind in the treatment of Leukemia. Her top areas of expertise are Rhabdomyosarcoma, Hepatoblastoma, Acute Lymphoblastic Leukemia (ALL), and Neuroblastoma. Dr. Haduong is currently accepting new patients.

Her clinical research consists of co-authoring 15 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 2 clinical trials in the study of Leukemia.

Specialties
Pediatric Hematology Oncology
Licenses
Hospitalist in CA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
View 2 Less Insurance Carriers -

Locations

1201 West La Veta Avenue, Orange, CA 92868

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

A Phase 1/ 2 Study of BAY 1895344 (Elimusertib, NSC#810486) in Pediatric Patients With Relapsed or Refractory Solid Tumors
A Phase 1/ 2 Study of BAY 1895344 (Elimusertib, NSC#810486) in Pediatric Patients With Relapsed or Refractory Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 08, 2025
Intervention Type: Drug
Study Drug: Elimusertib
Study Phase: Phase 1/Phase 2
A Phase 2 Study of DS-8201a (NSC# 807708) in Adolescents, or Young Adults With Recurrent HER2+ Osteosarcoma
A Phase 2 Study of DS-8201a (NSC# 807708) in Adolescents, or Young Adults With Recurrent HER2+ Osteosarcoma
Enrollment Status: Suspended
Publish Date: July 18, 2025
Intervention Type: Biological, Procedure
Study Drug: Trastuzumab Deruxtecan
Study Phase: Phase 2
Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias
Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2025
Intervention Type: Drug
Study Drug: Larotrectinib Sulfate
Study Phase: Phase 2
A Feasibility Trial of MLN4924 (Pevonedistat, TAK 924) Given in Combination With Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
A Feasibility Trial of MLN4924 (Pevonedistat, TAK 924) Given in Combination With Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Enrollment Status: Completed
Publish Date: April 13, 2025
Intervention Type: Drug
Study Drugs: Azacitidine, Cytarabine, Fludarabine Phosphate, Methotrexate, Pevonedistat, Hydrocortisone
Study Phase: Phase 1
A Phase 1 Study of Selinexor (KPT-330), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
A Phase 1 Study of Selinexor (KPT-330), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Drug, Other
Study Drug: Selinexor
Study Phase: Phase 1
A Phase 1 Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination With Temozolomide and Irinotecan
A Phase 1 Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination With Temozolomide and Irinotecan
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Drug, Other
Study Phase: Phase 1
A Phase 1 Trial of the CD123 X CD3 DART Molecule Flotetuzumab (NSC#808294) in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 Trial of the CD123 X CD3 DART Molecule Flotetuzumab (NSC#808294) in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: January 09, 2025
Intervention Type: Drug, Biological
Study Drugs: Cytarabine, Flotetuzumab
Study Phase: Phase 1
A Phase 1 Study of Pevonedistat (MLN4924), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of Pevonedistat (MLN4924), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: October 22, 2024
Intervention Type: Drug
Study Drugs: Irinotecan, Pevonedistat, Temozolomide
Study Phase: Phase 1
A Phase 1/2 Study of VX15/2503 in Children, Adolescents, or Young Adults With Recurrent or Relapsed Solid Tumors
A Phase 1/2 Study of VX15/2503 in Children, Adolescents, or Young Adults With Recurrent or Relapsed Solid Tumors
Enrollment Status: Completed
Publish Date: July 15, 2024
Intervention Type: Biological, Other
Study Drug: Pepinemab
Study Phase: Phase 1/Phase 2
A Phase 1 Study of AZD1775 (MK-1775) Concurrent With Local Radiation Therapy for the Treatment of Newly Diagnosed Children With Diffuse Intrinsic Pontine Gliomas
A Phase 1 Study of AZD1775 (MK-1775) Concurrent With Local Radiation Therapy for the Treatment of Newly Diagnosed Children With Diffuse Intrinsic Pontine Gliomas
Enrollment Status: Completed
Publish Date: January 31, 2024
Intervention Type: Drug, Other, Radiation
Study Drug: Adavosertib
Study Phase: Phase 1
A Phase 1 Study of LY2606368 (Prexasertib Mesylate Monohydrate) a CHK1/2 Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors
A Phase 1 Study of LY2606368 (Prexasertib Mesylate Monohydrate) a CHK1/2 Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Enrollment Status: Completed
Publish Date: December 20, 2023
Intervention Type: Other, Drug
Study Phase: Phase 1
A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug, Other
Study Drug: Entinostat
Study Phase: Phase 1
A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab
A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Biological, Other
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of AZD1775 (MK-1775) in Combination With Oral Irinotecan in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors
A Phase 1/2 Study of AZD1775 (MK-1775) in Combination With Oral Irinotecan in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: September 26, 2023
Intervention Type: Drug
Study Drugs: Adavosertib, Irinotecan Hydrochloride
Study Phase: Phase 1/Phase 2
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial Sarcoma
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial Sarcoma
Enrollment Status: Terminated
Publish Date: September 13, 2023
Intervention Type: Drug
Study Drugs: Ramucirumab, Gemcitabine, Docetaxel
Study Phase: Phase 1/Phase 2
A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors
A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors
Enrollment Status: Completed
Publish Date: August 17, 2021
Intervention Type: Drug
Study Phase: Phase 1
View 15 Less Clinical Trials

15 Total Publications

Cancer and Trauma Collide: Injury Patterns and Outcomes in the Pediatric Trauma Patient With Cancer.
Cancer and Trauma Collide: Injury Patterns and Outcomes in the Pediatric Trauma Patient With Cancer.
Journal: The American surgeon
Published: February 25, 2025
Similar Doctors
Elite in Leukemia
Dr. Deepa Bhojwani
Pediatric Hematology Oncology
Elite in Leukemia
Dr. Deepa Bhojwani
Pediatric Hematology Oncology

Childrens Hospital Los Angeles Medical Group Inc

4650 W Sunset Blvd, 
Los Angeles, CA 
 (32.7 miles away)
323-361-8408
Languages Spoken:
English
See accepted insurances

Deepa Bhojwani is a Pediatric Hematologist Oncology provider in Los Angeles, California. Dr. Bhojwani is rated as a Distinguished provider by MediFind in the treatment of Leukemia. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Epidural Lipomatosis, Bone Marrow Transplant, and Bone Marrow Aspiration.

Distinguished in Leukemia
Dr. Alan S. Wayne
Pediatric Hematology Oncology
Distinguished in Leukemia
Dr. Alan S. Wayne
Pediatric Hematology Oncology
4650 W Sunset Blvd, 
Los Angeles, CA 
 (32.7 miles away)
323-361-4100
Languages Spoken:
English
See accepted insurances

Alan Wayne is a Pediatric Hematologist Oncology provider in Los Angeles, California. Dr. Wayne is rated as a Distinguished provider by MediFind in the treatment of Leukemia. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Severe Combined Immunodeficiency (SCID), Infantile Neutropenia, and Bone Marrow Transplant.

Distinguished in Leukemia
Dr. Paul S. Gaynon
Pediatric Hematology Oncology
Distinguished in Leukemia
Dr. Paul S. Gaynon
Pediatric Hematology Oncology
4650 Sunset Blvd, 
Los Angeles, CA 
 (32.8 miles away)
323-361-2163
Languages Spoken:
English
See accepted insurances

Paul Gaynon is a Pediatric Hematologist Oncology provider in Los Angeles, California. Dr. Gaynon is rated as a Distinguished provider by MediFind in the treatment of Leukemia. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Adult T-Cell Leukemia, Kienbock's Disease, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Haduong's expertise for a condition
ConditionClose
      View All 13 Advanced Conditions
      View All 36 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile